---
document_datetime: 2025-11-28 08:35:45
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/fingolimod-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: fingolimod-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.8936121
conversion_datetime: 2025-12-28 00:11:26.172854
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Fingolimod Mylan

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a variation | 27/11/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000280709                     | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z - to implement changes to the Risk Management Plans for Fingolimod Mylan and Mulfiyna, following relevant updates to the Risk Management Plan of the innovator product Gilenya (Novartis Europharm Limited, EMEA/H/C/002202).   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000313477 | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                                                                                                                                       | 20/11/2025 | N/A |
| Variation type IA / EMA/VR/0000309576 | This was an application for a group of variations. B.II.e.4 Change in shape or dimensions of the container or closure (immediate                                                                                                                                                                                                                                                                                                                                                                                                                                        | 07/11/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | packaging) - B.II.e.4.a Non-sterile medicinal products - Accepted B.II.e.4 Change in shape or dimensions of the container or closure (immediate packaging) - B.II.e.4.a Non-sterile medicinal products - Accepted B.II.e.4 Change in shape or dimensions of the container or closure (immediate packaging) - B.II.e.4.a Non-sterile medicinal products - Accepted                                                                                                                                                                                                         |            |     |                  |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------|
| Article 61(3) / EMA/N/0000303376      | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contact details of local representative and the addition of the shortened pharmaceutical form 'Capsules' into brackets in Section 6; as well as update of the labelling to include the word 'hard' in section 1. under 'Minimum particulars to appear on unit dose blister' and to implement grey-shading to the pharmaceutical form and the INN in section 1. under 'Minimum particulars to appear on blisters' and under 'Minimum particulars to appear on unit dose blisters'. | 06/11/2025 |     | Labelling and PL |
| Variation type IB / EMA/VR/0000268233 | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                   | 26/06/2025 | N/A |                  |

<div style=\"page-break-after: always\"></div>

|                                       | B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished product - B.II.e.2.z Other changes - Accepted B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished product - B.II.e.2.z Other changes - Accepted B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished product - B.II.e.2.z Other changes - Accepted                         |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000246642 | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted | 08/05/2025 | 10/06/2025 | SmPC, Annex II, Labelling and PL | To update section 4.3 of the SmPC to include leukoencephalopathy (PML) as a new contraindication; update of section 4.4 of the SmPC to amend an existing warning on PLM and to add a new warning on immune reconstitution inflammatory syndrome (IRIS). Furthermore, section 4.8 of SmPC has been updated to add IRIS as ADR with frequency not know. The package leaflet has been updated accordingly. Annex II has also been brought in line with the reference product. In addition the local representatives in AT, FI, PL have been updated and update to QRD 10.4. To change the ATC Code for Fingolimod, from L04A A27 to L04A E01 as per the recent reclassification |

<div style=\"page-break-after: always\"></div>

|                                       | in ATC Code / ATC Vet Code - Accepted C.I.2.a To update section 4.3 of the SmPC to include leukoencephalopathy (PML) as a new contraindication; update of section 4.4 of the SmPC to amend an existing warning on PLM and to add a new warning on immune reconstitution inflammatory syndrome (IRIS). Furthermore, section 4.8 of SmPC has been updated to add IRIS as ADR with frequency not know. The package leaflet has been updated accordingly. Annex II has also been brought in line with the reference product. In addition the local representatives in AT, FI, PL have been updated and update to QRD 10.4. A.6 To change the ATC Code for Fingolimod, from L04A A27 to L04A E01 as per the recent reclassification by the   |            |     | by the WHO.   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------|
| Variation type IA / EMA/VR/0000245903 | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 28/01/2025 | N/A |               |